IL1B and atherosclerosis: On the other hand, the Cardiovascular Inflammation Reduction Trial indicated that low-dose methotrexate, an immune suppressant, did not decrease cardiovascular events in patients with stable atherosclerosis when it did not reduce the levels of IL-1β, IL-6, and C-reactive protein [74].